Belite Bio (NASDAQ:BLTE) Upgraded at Wall Street Zen

Belite Bio (NASDAQ:BLTE) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts have also commented on the stock. Benchmark reiterated a “buy” rating on shares of Belite Bio in a research note on Tuesday. Mizuho set a $223.00 price objective on shares of Belite Bio in a research report on Thursday, February 19th. Bank of America started coverage on Belite Bio in a research report on Monday, January 26th. They issued a “buy” rating and a $195.00 target price on the stock. Cantor Fitzgerald increased their target price on Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Maxim Group set a $200.00 price target on Belite Bio in a report on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $202.33.

Belite Bio Stock Up 0.4%

NASDAQ BLTE opened at $173.30 on Friday. Belite Bio has a 12-month low of $49.00 and a 12-month high of $200.00. The firm’s 50 day moving average is $170.11 and its 200-day moving average is $124.77. The company has a market capitalization of $6.50 billion, a PE ratio of -75.35 and a beta of -1.46.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.18. As a group, sell-side analysts expect that Belite Bio will post -1.17 EPS for the current year.

Institutional Trading of Belite Bio

Large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd grew its holdings in shares of Belite Bio by 28,200.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after purchasing an additional 282 shares in the last quarter. Bank of America Corp DE raised its stake in Belite Bio by 28.1% in the third quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after purchasing an additional 257 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Belite Bio during the fourth quarter worth about $103,000. Persistent Asset Partners Ltd acquired a new stake in Belite Bio during the fourth quarter worth about $108,000. Finally, GAMMA Investing LLC grew its stake in Belite Bio by 11.1% during the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after buying an additional 176 shares in the last quarter. 0.53% of the stock is owned by institutional investors and hedge funds.

Belite Bio News Roundup

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald published a bullish outlook that analysts say supports upside potential for BLTE shares; this contributed to positive investor sentiment today. Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says
• Positive Sentiment: Morgan Stanley is also cited as forecasting strong price appreciation for Belite Bio, helping lift the stock as momentum and analyst optimism draw buyer interest. Morgan Stanley Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Positive Sentiment: An American Banking News item highlights HC Wainwright’s continued bullish stance (Buy, $200 target), which can limit downside even as estimates shift. HC Wainwright Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Neutral Sentiment: Reported short‑interest figures appear to show zero shares and a 0.0 days‑to‑cover ratio — likely a data anomaly or reporting issue rather than meaningful new short activity. That makes the short‑interest data neutral for near‑term price direction.
• Negative Sentiment: HC Wainwright reduced its near‑term EPS forecasts in a March 3 research note: Q1 2026 EPS cut from ($0.56) to ($0.71), Q2 from ($0.56) to ($0.72), Q3 from ($0.57) to ($0.73), Q4 2026 from $5.80 to $4.05, and FY2026 from $4.12 to $1.89. Although the firm kept a Buy rating and $200 target, the sizable downward revisions to quarterly and full‑year earnings increase uncertainty around near‑term results and could pressure the stock if upcoming operational or clinical updates fall short. Belite Bio (BLTE) MarketBeat company page

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.